IMMX Stock Forecast: Immix Biopharma, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Immix Biopharma, Inc. is $23. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Immix Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (79): The shares have been drifting up relative to others.
Accruals (17): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IMMX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMMX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | Mizuho | Maintains | Outperform | $23 → $22 |
| 18 Nov 2026 | Morgan Stanley | Maintains | Overweight | $20 → $21 |
| 16 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $25 → $27 |
| 29 Sept 2026 | Needham | Maintains | Buy | $21 → $30 |
| 15 Sept 2026 | Mizuho | Maintains | Outperform | $15 → $26 |
| 11 Aug 2026 | Morgan Stanley | Maintains | Overweight | $20 → $19 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $25 |
| 22 July 2026 | Needham | Initiates | Buy | $21 |
| 18 June 2026 | B of A Securities | Initiates | Buy | $27 |
| 17 June 2026 | LifeSci Capital | Initiates | Outperform | — |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 27 Mar 2026 | Citizens | Reiterates | Market Outperform | — |
| 27 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Mar 2026 | Morgan Stanley | Initiates | Overweight | — |
| 9 Mar 2026 | Citizens | Initiates | Market Outperform | — |
| 9 Feb 2026 | Mizuho | Initiates | Outperform | — |
| 9 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IMMX.
This page is one stock. Monday covers all of them.
IMMX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IMMX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Immix Biopharma, Inc. returned +73.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IMMX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.8×
- EV / EBITDA
- —
Cheaper than 48% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −26.9%
- Return on assets
- −17.1%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immix Biopharma, Inc. has a market value of $590.0M and an enterprise value of $254.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$39.9M.
Free cash flow in the twelve months to 30 June 2026: −$39.1M.
Immix Biopharma, Inc. employs 21 people.
Data provided by Twelve Data
IMMX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IMMX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Immix Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IMMX
What is the IMMX stock price forecast for 2026-2027?
The median 12-month analyst price target for Immix Biopharma, Inc. is $23, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMMX stock a buy right now?
Of the 7 analysts covering Immix Biopharma, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immix Biopharma, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMMX?
As at 21 Nov 2026, Immix Biopharma, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).
Will IMMX stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $23, and Ticker Nerd's factor model ranks Immix Biopharma, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMMX stock forecast for 2030?
No analyst covering Immix Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.
How has IMMX stock performed over the past year?
Immix Biopharma, Inc. returned +73.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Immix Biopharma, Inc. do?
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors. The company also works on immune-dysregulated and inflammatory diseases through its proprietary therapeutic platforms. Immix Biopharma operates in the biotechnology sector, where its role is centered on advancing investigational treatments designed to address high-unmet-need conditions through cell therapy and precision drug delivery approaches. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma is positioned as a development-stage company focused on translating specialized oncology and immunology research into clinical programs.
CEO Dr. Ilya Rachman M.B.A., M.D., Ph.D. · 21 employees · United States · https://www.immixbio.com